Cell division cycle 7 (CDC7), a serine/threonine kinase, plays important roles in the initiation of DNA replication. 

TAK-931, a highly specific CDC7 inhibitor, exhibits antitumor efficacy and immunity. 

The flowcytometry-based immune profiling panel studies in J558 allograft syngeneic mouse models were performed at Medicilon. 

In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.

Reference

Tomoko Y. Morita, et al. Abstract P029: CDC7 inhibitor-induced replication stress generates inflamed aneuploid cells to sensitize immune checkpoint inhibitors. Mol Cancer Ther (2021) 20 (12_Supplement): P029. https://doi.org/10.1158/1535-7163.TARG-21-P029